|
1
|
Jemal A, Siegel R, Ward E, Murray T, Xu J,
Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin.
56:106–130. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jonker DJ, Maroun JA and Kocha W: Survival
benefit of chemotherapy in metastatic colorectal cancer: A
meta-analysis of randomized controlled trials. Br J Cancer.
82:1789–1794. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kohne CH, Cunningham D, Di Costanzo F,
Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer
M, Wils J, et al: Clinical determinants of survival in patients
with 5-fluorouracil-based treatment for metastatic colorectal
cancer: Results of a multivariate analysis of 3825 patients. Ann
Oncol. 13:308–317. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
André T, Boni C, Mounedji-Boudiaf L,
Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan
P, Bridgewater J, et al: Oxaliplatin, fluorouracil, and leucovorin
as adjuvant treatment for colon cancer. N Engl J Med.
350:2343–2351. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Eisenman ST, Gibbons SJ, Verhulst PJ,
Cipriani G, Saur D and Farrugia G: Tumor necrosis factor alpha
derived from classically activated ‘M1’ macrophages reduces
interstitial cell of Cajal numbers. Neurogastroenterol Motil.
29:2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mocellin S, Rossi CR, Pilati P and Nitti
D: Tumor necrosis factor, cancer and anticancer therapy. Cytokine
Growth Factor Rev. 16:35–53. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
van Horssen R, Ten Hagen TL and Eggermont
AM: TNF-alpha in cancer treatment: Molecular insights, antitumor
effects, and clinical utility. Oncologist. 11:397–408. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu Y and Zhou BP:
TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and
invasion. Br J Cancer. 102:639–644. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen G and Goeddel DV: TNF-R1 signaling: A
beautiful pathway. Science. 296:1634–1635. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sedger LM and McDermott MF: TNF and
TNF-receptors: From mediators of cell death and inflammation to
therapeutic giants-past, present and future. Cytokine Growth Factor
Rev. 25:453–472. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stuelten CH, DaCosta Byfield S, Arany PR,
Karpova TS, Stetler-Stevenson WG and Roberts AB: Breast cancer
cells induce stromal fibroblasts to express MMP-9 via secretion of
TNF-alpha and TGF-beta. J Cell Sci. 118:2143–2153. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Harrison ML, Obermueller E, Maisey NR,
Hoare S, Edmonds K, Li NF, Chao D, Hall K, Lee C, Timotheadou E, et
al: Tumor necrosis factor alpha as a new target for renal cell
carcinoma: Two sequential phase II trials of infliximab at standard
and high dose. J Clin Oncol. 25:4542–4549. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ohri CM, Shikotra A, Green RH, Waller DA
and Bradding P: Tumour necrosis factor-alpha expression in tumour
islets confers a survival advantage in non-small cell lung cancer.
BMC Cancer. 10:3232010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sethi G, Sung B and Aggarwal BB: TNF: A
master switch for inflammation to cancer. Front Biosci.
13:5094–5107. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Terzic J, Grivennikov S, Karin E and Karin
M: Inflammation and colon cancer. Gastroenterology.
138:2101–2114.e5. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hamanishi J, Mandai M, Iwasaki M, Okazaki
T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N,
et al: Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+
T lymphocytes are prognostic factors of human ovarian cancer. Proc
Natl Acad Sci USA. 104:pp. 3360–3365. 2007; View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ray A and Dittel BN: Isolation of mouse
peritoneal cavity cells. J Vis Exp. pii:14882010.
|
|
19
|
Rossi CR, Foletto M, Pilati P, Mocellin S
and Lise M: Isolated limb perfusion in locally advanced cutaneous
melanoma. Semin Oncol. 29:400–409. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Christoforidis D, Martinet O, Lejeune FJ
and Mosimann F: Isolated liver perfusion for non-resectable liver
tumours: A review. Eur J Surg Oncol. 28:875–890. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Orosz P, Echtenacher B, Falk W, Rüschoff
J, Weber D and Männel DN: Enhancement of experimental metastasis by
tumor necrosis factor. J Exp Med. 177:1391–1398. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Suganuma M, Okabe S, Marino MW, Sakai A,
Sueoka E and Fujiki H: Essential role of tumor necrosis factor
alpha (TNF-alpha) in tumor promotion as revealed by
TNF-alpha-deficient mice. Cancer Res. 59:4516–4518. 1999.PubMed/NCBI
|
|
23
|
Tsimberidou AM, Waddelow T, Kantarjian HM,
Albitar M and Giles FJ: Pilot study of recombinant human soluble
tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:
Fc; Enbrel) in patients with refractory multiple myeloma: Increase
in plasma TNF alpha levels during treatment. Leuk Res. 27:375–380.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Giordano M, Roncagalli R, Bourdely P,
Chasson L, Buferne M, Yamasaki S, Beyaert R, van Loo G,
Auphan-Anezin N, Schmitt-Verhulst AM and Verdeil G: The tumor
necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a
brake on antitumor activity of CD8 T cells. Proc Natl Acad Sci USA.
111:pp. 11115–11120. 2014; View Article : Google Scholar : PubMed/NCBI
|
